Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB1148 in elective bowel resection
NCT04100447Phase 1Completed
- Start
- Nov 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LB1148 in postoperative ileus (POI) and Abdominal Adhesions. Primary endpoint: Treatment-Emergent Adverse Events at Day 30. Started Nov 2018; status: completed.
02
Drugs
LB1148
03
Conditions
postoperative ileus (POI)Abdominal Adhesions
Beyond the preview
Go deeper on NCT04100447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04100447.